Fig. 5: TMEM170B performed as an endogenous inhibitor of the Wnt/β-catenin pathway in breast cancer | Cell Death & Disease

Fig. 5: TMEM170B performed as an endogenous inhibitor of the Wnt/β-catenin pathway in breast cancer

From: Transmembrane protein 170B is a novel breast tumorigenesis suppressor gene that inhibits the Wnt/β-catenin pathway

Fig. 5

The Wnt/TCF activity in the stable MCF7 (a) or MDA-MB-231 (b) cells. The mRNA (c) and protein (d) levels of β-catenin downstream targets in the stable MCF7 cells were measured by real-time PCR and immunoblotting. The mRNA (e) and protein (f) levels of β-catenin downstream targets in stable MDA-MB-231 cells were measured by real-time PCR and immunoblotting. Western blot analysis of the protein levels of cytoplasm or nuclear β-catenin in the stable MCF7 (g) or MDA-MB-231 (h) clones. i Immunofluorescence analysis of the subcellular localization of β-catenin in indicated breast cancer cell clones. Representative IHC for TMEM170B and β-catenin expression of the indicated xenograft tumor tissues (n = 5) in the stable MCF7 (j) or MDA-MB-231 (k) clones. Scale bar represents 50 µm. The interaction (l) of TMEM170B and β-catenin was analyzed by co-immunoprecipitation. The mRNA (m) and protein (n) levels of β-catenin downstream targets in the stable MCF7 cells treated with the indicated si β-catenin were detected by real-time PCR and immunoblotting. Data are presented as mean ± S.E.M. *P < 0.05 vs. CTRL, **P < 0.01 vs. CTRL, ***P < 0.001 vs. CTRL

Back to article page